While the current valuation profile of Vitrolife requires more than the current stagnant growth profile, yesterdays ~20% sell-off (despite a...
Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and a significant reported EBIT loss driven...
Redeye updates on Vitrolife after a site visit and a change of lead analyst.
Vitrolife faces a tough 2025, and we expect this to continue during H2 2025, at best, at a fading rate.
Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025.
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
In the Asian region Vitrolife faces a challenging period.
The recent share price reaction is an overreaction.
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constant currencies (CER).
Vitrolife continues stabilise its growth rate and is approaching high single-digit growth.
Vitrolife delivered a consecutive positive organic growth recovery with 7% organic growth in constant currencies (CER), this time without su...
- Mixed Q3, but with signs of improvements - We revise EBITDA down by 1.
Vitrolife continues to improve its organic growth, and the company has delivered two quarters with close-to-market growth.
4.7% miss on EBITDA vs cons Consumables and Technology good, still challenges in Genetics Estimates likely down 1-3% on EBITDA for consensus...
Sales growth of +7.8% and 20% EBIT margin in Q3e EBITDA '24e-'26e revised down 1.
Vitrolife delivered a surprising organic growth recovery with 4% organic growth and even if there was support from larger orders the company...
- Higher sales and gross margin in Q2 - EBITDA revised up 2.
Despite a softer period for Vitrolife’s typically reliable Consumables and APAC, the company delivers a distinct positive surprise during Q2...
- 10% beat on EBITDA vs cons - Strong growth in Technology, but continued weakness in Genetics - Estimates likely up 2-4% on EBITDA for cons...
Q2'24e expectations We forecast flat (0%) organic growth rate for Vitrolife and a marginally higher EBITDA margin in Q2.
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024.
Flat organic sales growth, due to Genetics EBITDA revised down 1.
The recorded sales growth is 0% in local currency due to an extended headwind for the Genetics business even if this was better than expecte...
Continued weakenss in Genetics holding back sales growth Good growth in Consumables and Technology Estimates likely down 1-2% on EBITDA for ...
Q1'24 due 18 April +1.8% organic sales growth in Q1'24e EBITDA '24e-'26e up +1.
Vitrolife’s Q4 delivers a high 56.9% gross margins despite a quarter with an unfavorable Technology and Consumable mix.
5.2% organic sales growth, improving margins EBITDA up 1.
Sales and EBITDA inline with pre-announcement 31% organic growth in Technology Estimates likely up 1-2% on EBITDA Q4 results Vitrolife pre-...
As a result of the earlier trading update, the main interest is in the outlook, especially for the US-related Genetic Services business.
Vitrolife will release the Q4 results on 2 February.
Vitrolife provides an update ahead of the total Q4 due on 2 February.
SEK 4.3bn impairment charge of Igenomix 1.6% beat on preliminary Q4 adj EBITDA Minor positive earnings revisions expected Impairment charge...
Q4'23 results due 2 February 23e EBITDA cut 1.4% and down 11.
Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitrolife.
New financial targets Promising earnings outlook unchanged Limited earnings revisions expected, down 2-4% on EBITDA New strategy with focus...
Vitrolife’s Q3 confirms that Vitrolife is going through a period with softer organic growth, even below our expectations at 3% in Q3.
3% organic growth and improved margins EBITDA down 2-5% for '23e-'25e 52-60% below historical multiples, but above sector peers EMEA region...
Q3 confirms that Vitrolife is going through a period with softer organic growth, even below our expectations, at 3% in Q3.
Vitrolife is going through a period with softer organic growth in the 3-6% which compares with a more typical 8-11% strict organic growth fo...
APAC and Consumables delivers another strong quarter with double digit growth.
Consumables did not make up for a softer period in Genomic Services and Technologies.
Vitrolife enters 2023 with good progress and 9% organic growth.
Q1 results show market share gains and operation improvement '23e-'25e EBITDA up 1% Trading at 34x '23e EV/EBITDA vs.
Sales +2% vs. cons, adj. EBIT -2% Expect relatively unchanged estimates Conference call at 10:00 CET Q1 results Sales came in at SEK 854m (+...
Vitrolife’s enters 2023 with good progress. The organic growth is 9%, with support from all three lines of business.
Vitrolife is in good health and the company ended 2022 on a strong finish and a positive outlook ahead for the rest of 2023.
Better organic growth, less impressive margins '23e-'24e EBIT cut 3% Trading at 34x '23e EV/EBITDA vs.
After a period with pressure on margins and especially the organic growth, the 11% organic growth in Q4 is a welcome positive surprise.
Consumables slump signalling bigger slowdown We cut ‘23e EBIT by 4% on lower growth and margins Trading at 22x CFY EV/EBITDA (5Y avg.
Sales +3% and EBITDA +9% vs. cons, respectively Expect cons to raise EBITDA estimates by 3-4% Conference call at 10:00 CET Q3 results Sales...
Vitolife's Q3 is mixed bag with a softer Europe and a negative product mix resulting in 5% organic growth (comparable proforma CER) and tem...
The Vitrolife share appreciated +4000% during his time The timing for his retirement is logical Strong board and owners to aid search for ...
EBITDA 8% above cons, discontinuing non-core areas Initial signs of lower IVF cycle growth near-term EBITDA up 5-8% for ’22e-’24e, EV/EBIT...
Vitrolife continues to improve organic growth and margins with good balance support from all regions and both technology and consumables.
Sales 7% above cons, EBITDA 8% Streamlining in Genetic Services Cons ‘22e EBITDA to come up ~5% Q2 figure Sales: SEK 829m (7% vs.
High out-of-pocket costs cut growth in ‘09-10 (GFC) Caution reflected in estimates; 35x ‘22e EV/EBITDA Q2: solid 13% organic growth, q-o-q ...
Vitrolife’s previous Q1 confirms more normal activity with improved organic growth to 11% from the last Q4 dip to 4%.
Global IVF market back at pre-pandemic levels On 15 July, Vitrolife released its full Q2’21 report, which was broadly in line with the pre-a...
Acquires IVF diagnostics company Igenomix Pays 36x LTM EV/EBITDA Pre-announced Q2’21 – CER sales growth of 94% On Thursday 7 July, Vitrolife...
